YL202

DRUG4 trials

Conditions

Breast CancerCervical CancerColorectal CancerLocally Advanced or Metastatic Breast CancerLocally Advanced or Metastatic Solid TumorsNon Small Cell Lung CancerNon-Small Cell Lung Cancer

Phase 1

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active, not recruitingNCT05653752

MediLink Therapeutics (Suzhou) Co., Ltd.Breast Cancer, Non Small Cell Lung Cancer

Start: 2022-12-20End: 2026-12-01Target: 80Updated: 2026-05-15

Phase 2

A Study of YL202 in Patients With Advanced Solid Tumors

RecruitingNCT07202364

MediLink Therapeutics (Suzhou) Co., Ltd.Cervical Cancer, Colorectal Cancer, Locally Advanced or Metastatic Solid Tumors +1

Start: 2025-08-04End: 2027-02-28Target: 100Updated: 2026-03-09

Phase 3

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT07416994

MediLink Therapeutics (Suzhou) Co., Ltd.Non-Small Cell Lung Cancer

Start: 2026-03-18End: 2028-08-31Target: 440Updated: 2026-06-15

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

RecruitingNCT07461454

MediLink Therapeutics (Suzhou) Co., Ltd.Locally Advanced or Metastatic Breast Cancer

Start: 2026-03-17End: 2028-06-30Target: 376Updated: 2026-05-26

Related Papers

BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-28

YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.